Member Info for Kashdog

Like I said Lucy, I don’t care! 🤷‍♂️

Not even a question for me. I don’t care… this is one of those shares where you can own a few million for a few quid.

It then becomes a casual watch until the SP moves significantly north, then the gamblers “rush” kicks in … until it heads south again but because those shares cost buttons, it doesn’t matter not one jot.… it’s a fun share!…enjoy the ride win or lose!

Unless you are a complete investing moron who gambled more than they wanted to lose then they revert to being that anonymous nasty commentator!…fun to watch on the rare occasion I pop in here!… yay! 🤣🤣🤣

I was referring to the compression skid in my last

John Buggenhagen was the COO at the time!… a real smoke and mirrors guy who claimed he had completed a survey but never did. He used old data and dressed it up. What a twat he was.

Slovenia will not easily accept a finding against them. The appeal process will take years as Slovenia will slow it down and then, when every appeal avenue has been exhausted, getting the compensation from the Slovenian government is unlikely.

I recall that Ascent bought a mobile compression skid in 2019 for PG10. It never got installed. I believe it was sold in some sort of unrecorded deal as it never showed in the accounts, in line with the usual lack of transparency with this company.

Miavoce, Genmab will, potentially, pay £630 million for just one monoclonal antibody so why would Scancell let 25% of GT go for 50 million?

Anyone see an equivalent ego here with Scin and Trump?…. Both have a belief that they are right, nobody else has an opinion of any value. Just like Trump , if you disagree with him you will be insulted. We are lucky that his opinion has no impact on anything and I mean anything, unlike Trump who has some global influence whether you like it or not.

Scin clearly has some knowledge but his presentation of it is ugly as fu*k which devalues his input so best ignored!

Overall, I thought it was a confidence builder. Glymab Therapeutics will have its own management team and recruit different skills to those in Scancell holdings.

Reassurance from Seth on the cash runway to progress both companies. Ongoing talks with potential partners and investors but the data expected by the end of July is expected to increase the value of the company. A NASDAQ listing is a potential for the future but not yet.

A positive presentation but not earth moving and maybe that’s the reason the SP has just dropped below 10p…..which makes it a “buy” for me!!!!……based on the expected “positive” data due at the end of July.

Not sure if I have a valid concern that the newly registered company, if wholly owned by Scancell, will not somehow, down the line, be separated from the mothership under “new” ownership depriving current Shareholders of value.

I wonder how much influence has been exerted here with our institutional investors Redmile and Vulpes.

Splitting the company does have a whiff of “For Sale” about it.

Surely if the Glymabs piece is so good, would it not add significant value to Scancell Holdings as a whole if a buy out was on the cards?

Bloomers, nobody can remove Jerome Powell as Fed Chair, not even the President.

It would require a change in the law passed by congress……which Trump has filed to do as he really hates Powell on a personal basis.

I had the same idea and actually exchanged Sterling for new Israeli Shequels but hit a wall that made me lose interest.

These days, if it ain’t easy, I just give up! 😁

Checking in, as I am won’t to do on occasion!…nothing of value to add but have a question!…Scinv, what do you do for fun? any hobbies or activities that you find enjoyable or exciting? 🤔

Maybe Merck are backing the wrong horse!…🤔

Thanks for that Bermuda!…I shall move back to “Strong buy” from “Hold”…🤪

SCIB1 entered clinical trials in 2010…15 years ago and there was at that time a tie up with Immuneregen.

Anyone know what happened to this?…second question is 15 years reasonable for a candidate not to be bought to market?

Below is an extract from “Fierce Pharma” dated 2010.

“ Hal Siegel Ph.D., ImmuneRegen’s Chief Scientific Officer, commented: “We are excited to be commencing this relationship with Scancell. As ImmuneRegen and Scancell move towards the clinic independently, we feel this is the ideal time to collaborate on this project, with the goal of evaluating the combination of Scancell’s dendritic cell targeting technology as applied to these melanoma antigens** and ImmuneRegen’s Homspera®, which has shown dendritic cell immunostimulatory activity via dendritic cell responses to TRP2 directed against melanoma tumors. Ideally, we could be creating a combined product that represents the ‘next generation’ of cancer vaccine technology.”

I think that after the poster / conference events that even without an RNS the SP will rise on FOMO.

Perhaps, even with the spread, today’s price could be a final opportunity to get in low.

As always, investing on AIM is still gambling even if some of us think we are into a sure thing!…place your bets! 🤞

UXM, nothing written on this, or any other BB, has any effect on the SP.

Rampers and De-Rampers comments are just unsupported personal opinions.

MM’’s have their “tools” and “algo’s” that support their decisions.

To believe you can influence them with comments here is both naive and arrogant.

Good Luck DD77 👍

Me too GF…..ours are bought in Halifax S&S ISA’s so will not show in the “Trades” tab on this site. Grabbed at 7.97p 👍